The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): updated real-world (RW) data from US MM-6.
 
Saulius Kazmiems Girnius
Consulting or Advisory Role - Akcea Therapeutics; Celgene; Genentech; Takeda
Speakers' Bureau - Celgene; Takeda
Research Funding - Genentech; Takeda
Travel, Accommodations, Expenses - Celgene; Genentech; Takeda
 
Habte Aragaw Yimer
Consulting or Advisory Role - Amgen; Celgene; Epizyme; Seagen
Speakers' Bureau - AstraZeneca; Janssen
 
Sudhir Manda
No Relationships to Disclose
 
Christopher A. Yasenchak
Honoraria - Seagen; Takeda
Speakers' Bureau - BeiGene
Research Funding - Seagen
 
Veena Charu
No Relationships to Disclose
 
Roger M. Lyons
Employment - Texas Oncology; Texas Oncology; US Oncology; US Oncology
Leadership - Texas Oncology; Texas Oncology; US Oncology; US Oncology
Stock and Other Ownership Interests - Texas Oncology; Texas Oncology; Texas Oncology; Texas Oncology
Research Funding - Takeda; Takeda; Takeda; Takeda
Travel, Accommodations, Expenses - Texas Oncology; Texas Oncology; US Oncology; US Oncology
 
Suman Kambhampati
No Relationships to Disclose
 
Reumu E. Birhiray
Consulting or Advisory Role - Abbvie; Amgen; Array BioPharma; Bristol-Myers Squibb; Coherus BioSciences; Dova Pharmaceuticals; Janssen-Ortho; Kite, a Gilead company; Novartis; Pfizer; Pharmacyclics
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Clovis Oncology; Dova Pharmaceuticals; Exelixis; Genomic Health; Incyte; Insys Therapeutics; Janssen; Karyopharm Therapeutics; Lilly; Novartis; Pfizer; Puma Biotechnology; Seagen; Tesaro
 
Haresh S. Jhangiani
No Relationships to Disclose
 
Ralph V. Boccia
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Rigel (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
 
Presley Whidden
Employment - Millennium
Stock and Other Ownership Interests - Abbott; Abbvie; Millennium
 
Kim Bogard
Employment - Millennium
Stock and Other Ownership Interests - Millennium
Travel, Accommodations, Expenses - Millennium
 
Dasha Cherepanov
Employment - Millennium
Stock and Other Ownership Interests - Millennium
Consulting or Advisory Role - Millennium
Travel, Accommodations, Expenses - Millennium
Other Relationship - Millennium
 
Stephen Joseph Noga
Employment - Millennium
 
Robert M. Rifkin
Employment - McKesson
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Coherus BioSciences; Mylan; Takeda